Literature DB >> 6106643

Pharmacological effects of topical timolol in the rabbit eye.

S P Bartels, H O Roth, M M Jumblatt, A H Neufeld.   

Abstract

The ability of timolol to act as a beta-adrenergic antagonist in the cornea and in the iris--ciliary body of albino rabbits is reported. In vitro, timolol potently blocks the isoproterenol-stimulated synthesis of cAMP. In the iris-ciliary body, the apparent inhibition constant (K1) for timolol is 0.6 nM, indicating that timolol is approximately seven times more potent than propranolol. Topical timolol (0.5% and 4%) rapidly inhibits the beta-adrenergic--stimulated synthesis of cAMP in both corneal and iris--ciliary body tissues. Within 3 hr, however, the iris--ciliary body tissue regains its ability to produce large amounts of cAMP when challenged in vitro with isoproterenol. The washout of timolol from corneal tissue is more protracted. Intraocular pressure measurements by anterior chamber cannulation of anesthetized rabbits indicate that topical timolol (0.5% and 4%) has no significant influence on intraocular pressure. These concentrations of timolol significantly decrease heart rate but do not affect femoral arterial blood pressure. Because of the marked potency of timolol clinically, we conclude that the effects of the drug in the rabbit do not completely account for its therapeutic efficacy in humans, which must depend on more complex pharmacological actions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106643

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Replication of ciliary vasomotor effects with controlled intravascular corrosion casting.

Authors:  E M Van Buskirk; D R Bacon; W F Fahrenbach
Journal:  Trans Am Ophthalmol Soc       Date:  1989

2.  The role of beta 2-adrenoceptors in the IOP-lowering effect of adrenaline.

Authors:  H C Innemee; P A van Zwieten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

3.  Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.

Authors:  Jason Yeh; Daniel Kravitz; Brian Francis
Journal:  Clin Ophthalmol       Date:  2008-06

4.  Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.

Authors:  Muhammad Irfan Kamaruddin; Momoko Nakamura-Shibasaki; Yu Mizuno; Yoshiaki Kiuchi
Journal:  Clin Ophthalmol       Date:  2017-03-31

5.  Effects of aqueous suppressants and prostaglandin analogues on early wound healing after glaucoma implant surgery.

Authors:  Kyoung In Jung; Jung Eun Woo; Chan Kee Park
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

Review 6.  Current Advances in Nano-Based and Polymeric Stimuli-Responsive Drug Delivery Targeting the Ocular Microenvironment: A Review and Envisaged Future Perspectives.

Authors:  Siphokazi B K Dludla; Leshasha T Mashabela; Brian Ng'andwe; Pedzisai A Makoni; Bwalya A Witika
Journal:  Polymers (Basel)       Date:  2022-08-30       Impact factor: 4.967

7.  Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans.

Authors:  Alex Ilechie; Samuel Abokyi; Gifty Boateng; George Asumeng Koffuor
Journal:  Niger Med J       Date:  2016 Mar-Apr

8.  Effects of timolol maleate eye drops on experimentally dilated cardiomyopathy and healthy rabbits.

Authors:  Mitsuhiro Isaka; Reimi Hayashida; Yuumi Tamashima; Ryuji Araki
Journal:  Open Vet J       Date:  2021-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.